Jun 9, 2026 · 7 min
WPP rallies as GSK rebuilds oncology and Monte Paschi draws bids
WPP Gains, GSK Falls, Monte Paschi Up
The episode connects advertising’s AI exposure, a major pharmaceutical acquisition, and Italy’s contested banking landscape.
- 1WPP’s shares surged after an analyst argued artificial intelligence poses less threat to advertising than feared.
- 2GSK agreed to acquire US biotech firm Nuvalent for $10.6 billion to strengthen its oncology portfolio.
- 3Monte dei Paschi remains at the center of an ongoing bidding war in Italy’s banking sector.
Don't miss
GSK’s $10.6 billion Nuvalent acquisition stands out as the clearest strategic bet, aimed at rebuilding the company’s oncology portfolio.
The brief
WPP’s stock surged after a positive analyst rating challenged the idea that artificial intelligence will severely disrupt the advertising sector.
GSK is pursuing a $10.6 billion acquisition of US biotech firm Nuvalent, using the deal to rebuild its oncology portfolio.
The episode also follows the ongoing bidding war for Italy’s Monte dei Paschi bank, where competing interest keeps the stock in focus.
Together, the stories show three distinct forces moving European shares: changing technology expectations, pharmaceutical dealmaking, and banking consolidation.
Featuring
Giancarlo GiorgettiListen to the full episode and explore every guest, topic, and moment on PodLume.